Traceability for cancer therapy

November 20, 2012
The secondary standard ionisation chambers at NPL that were used in the establishment of traceable 177Lu measurements at hospitals.

Scientists from the National Physical Laboratory (NPL) have worked to establish traceability for a molecular radiotherapy treatment for patients suffering from neuroendocrine tumours.

Neuroendocrine tumours are usually found in the or lungs and arise from hormone-producing cells. A new treatment involves the administration of a peptide, radiolabelled with the beta- and gamma-emitting radionuclide Lutetium-177 (177Lu), which irradiates the widespread without causing excessive damage to surrounding healthy tissue. The treatment can also be followed by , taking advantage of the gamma-emission of the radionuclide.

Following a series of clinical trials, this radiopharmaceutical is now beginning to be used routinely for molecular radionuclide therapy (MRT) throughout the UK and Europe.

A team of NPL scientists first established a link to the International Reference System by standardising 177Lu as part of an international comparison in 2011. Once that had been established, NPL invited UK and European hospitals that regularly use this radionuclide to participate in a blind exercise to measure the radioactivity in samples of 177Lu. From the results of this exercise, the hospitals could demonstrate traceability, ensuring regulatory compliance and . The results showed that the majority of participants have the capability to measure the 177Lu activity to within 2%, with only three participants showing variations higher than this.

The same team of scientists is now working on the next important step towards establishing traceability for 177Lu imaging, within the framework of a European Metrology Research Programme (EMRP) project called 'Metrology for Molecular Radiotherapy'.

Explore further: New radioisotope will improve cancer therapy

Related Stories

New radioisotope will improve cancer therapy

April 22, 2011

The high neutron flux at the Institut Laue-Langevin (ILL) has produced samples of 161Tb, an isotope of terbium with better properties for cancer therapy than existing radiopharmaceutical treatments. Researchers led by Paul ...

High-impact radiopeptide therapy halts neuroendocrine cancer

June 6, 2011

Research introduced at SNM's 58th Annual Meeting could be a sign of hope for patients with neuroendocrine cancer not responding well to standard therapies. Most radiotherapies use medical isotopes that emit beta radiation. ...

Benefits of radionuclide therapy for neuroendocrine tumors

September 20, 2011

According to new Dutch research featured in the September issue of The Journal of Nuclear Medicine, a peptide receptor radiolabeled therapy (PRRT), [177Lu-DOTA0,Tyr3]Octreotate (177Lu-octreotate) , is effective not only in ...

Radiotherapy doses to be more accurate

April 13, 2012

Cancer patients undergoing radiotherapy treatments in future will be safer thanks to a collaborative piece of research by NPL, the University of Montreal, and McGill University which will result in improved measurement consistency.

Recommended for you

Combination therapy can prevent cytostatic resistance

November 26, 2015

Researchers at Karolinska Institutet have found a new way of preventing resistance to cytostatics used in the treatment of cancers such as medulloblastoma, the most common form of malignant brain tumour in children. The promising ...

Forecasting the path of breast cancer in a patient

November 23, 2015

USC researchers have developed a mathematical model to forecast metastatic breast cancer survival rates using techniques usually reserved for weather prediction, financial forecasting and surfing the Web.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.